GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galera Therapeutics Inc (NAS:GRTX) » Definitions » 5-Year Yield-on-Cost %

Galera Therapeutics (Galera Therapeutics) 5-Year Yield-on-Cost % : 0.00 (As of May. 26, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Galera Therapeutics 5-Year Yield-on-Cost %?

Galera Therapeutics's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for Galera Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



GRTX's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.8
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Galera Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Galera Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galera Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galera Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Galera Therapeutics's 5-Year Yield-on-Cost % falls into.



Galera Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Galera Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Galera Therapeutics  (NAS:GRTX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Galera Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Galera Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Galera Therapeutics (Galera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 134, Malvern, PA, USA, 19355
Galera Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Its lead product candidate, GC4419, is a small molecule dismutase mimetic developed for the reduction of severe oral mucositis, or SOM.
Executives
Mark Bachleda officer: Chief Commercial Officer C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BOULEVARD, #110, MALVERN PA 19355
Chris Degnan officer: Chief Financial Officer C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Mel Sorensen director, officer: President and CEO 7 RAPPS RUN DRIVE, MALVERN PA 19355
Eugene P. Kennedy officer: Chief Medical Officer 2503 SOUTH LOOP DRIVE, AMES IA 50010
Linda West director C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD., #110, MALVERN PA 19355
Jennifer Evans Stacey officer: See Remarks AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Jon T Holmlund officer: Chief Medical Officer
Lawrence M Alleva director 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Novo Holdings A/s 10 percent owner, other: SEE REMARKS TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Joel F. Sussman officer: Chief Accounting Officer C/O GALERA THERAPEUTICS, INC., 2 W LIBERTY BLVD. #110, MALVERN PA 19355
Novartis Bioventures Ltd 10 percent owner C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Clarus Iv-a, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Blackstone Clarus Gp L.p. 10 percent owner C/O THE BLACKSTONE GROUP INC., 345 PARK AVENUE, NEW YORK NY 10154
Sofinnova Venture Partners Ix, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025